LDB
BMRN icon

Lee, Danner & Bass’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lee, Danner & Bass’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150
Closed -$9.86K – 277
2024
Q4 		$9.86K Buy
+150
New +$10K ﹤0.01% 533

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lee, Danner & Bass's BMRN Position: Q1 2025 in Review

Lee, Danner & Bass sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 150 shares — an estimated $9.86K sold.

Lee, Danner & Bass first reported a position in BMRN in Q4 2024 and held it in 1 quarter. The position peaked at $9.86K in Q4 2024. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Lee, Danner & Bass reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Lee, Danner & Bass sold 150 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $9.86K.
  • Lee, Danner & Bass first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Lee, Danner & Bass's BioMarin Pharmaceuticals position peaked at $9.86K in Q4 2024.
  • 584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Lee, Danner & Bass's 13F filing for Q1 2025, filed 29 Apr 2025.